Last updated: February 27, 2026
What Is NDC 00169-1912?
NDC 00169-1912 corresponds to Rituximab (brand: Rituxan), a monoclonal antibody used primarily to treat non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and certain autoimmune diseases. The drug is marketed by Genentech, a Roche subsidiary.
Market Size and Key Drivers
Current Market Size
As of 2023, Rituximab's global market size stands at approximately $3.5 billion, with the United States accounting for around 60% of sales. The drug's primary indications include hematologic cancers and autoimmune conditions.
Growth Drivers
- Expanding Indications: The FDA approval of Rituximab for additional autoimmune diseases and follicular lymphoma boosts sales.
- Biosimilar Entry: Several biosimilar versions have entered markets since 2018, intensifying competition.
- Pricing Dynamics: Historically high prices, with annual treatment costs ranging from $30,000 to $100,000 depending on indications.
Market Segments
| Segment |
Market Share (2023) |
Key Players |
| Oncology (non-Hodgkin, CLL) |
65% |
Rituximab, Gazyva (Gilead), MabThera (Roche) |
| Autoimmune diseases |
35% |
Rituximab, biosimilars |
Geographic Breakdown
| Region |
Share of Revenue |
Key Trends |
| US |
60% |
Established payer networks, high treatment rates |
| EU |
25% |
Growing adoption, biosimilar competition |
| Rest of World |
15% |
Market entry growing, regulatory hurdles |
Competitive Landscape
Major Competitors
- Gazyva (obinutuzumab): A CAR T-cell therapy alternative for certain lymphomas.
- Biosimilars: Multiple approved biosimilars (e.g., Truxima, Ruxience) have captured approximately 35% of Rituximab sales since 2020 in the US.
Patent and Regulatory Environment
- Original patents expired in 2016.
- Biosimilar competition intensified following patent cliff.
- Patent litigations and exclusivity periods vary by jurisdiction, influencing price and market control.
Market Share Shifts
Biosimilar penetration in the US increased from 10% in 2018 to approximately 35% in 2023, exerting downward pressure on annual treatment costs and overall pricing.
Price Projections (2023–2028)
Current Pricing
- List Price (US): Approximately $4,700 per 10-mg vial.
- Average Annual Treatment Cost: Ranges from $30,000 to $100,000 depending on dosage and indication.
- Biosimilar Pricing: Typically 10–20% lower than the reference product; recent biosimilar prices are around $4,000 per vial.
Price Trends
| Year |
List Price per Vial |
Estimated Average Treatment Cost |
Key Assumptions |
| 2023 |
$4,700 |
$35,000 |
Stable list price, biosimilar market share at 35% |
| 2024 |
$4,500 |
$33,000 |
Slight list price reduction, increased biosimilar adoption |
| 2025 |
$4,300 |
$31,000 |
Biosimilar competition intensifies, further price erosion |
| 2026 |
$4,000 |
$29,000 |
Marginal price decreases, new biosimilar approvals |
| 2027 |
$3,800 |
$27,000 |
Further biosimilar penetration, payer discounts |
| 2028 |
$3,700 |
$25,000 |
Market stabilization, alternative treatment options emerge |
Drivers of Price Decline
- Biosimilar market share expected to reach 50% by 2026.
- Payer and hospital negotiations push prices downward.
- Price erosion influenced by increases in competition and formulary preferences.
Future Market Opportunities and Risks
Opportunities
- Expansion into new autoimmune diseases.
- Development of next-generation biosimilars with lower costs.
- Increasing global adoption in emerging markets with growing healthcare infrastructure.
Risks
- Price reductions driven by biosimilar competition.
- Regulatory delays for new indications.
- Patent litigation extending exclusivity periods in specific jurisdictions.
Key Takeaways
- The Rituximab market is sizable but faces increasing biosimilar competition, leading to price declines.
- US market dominates, but growth in emerging markets offers new revenue opportunities.
- Average treatment costs are expected to decrease gradually, driven by biosimilar entry and payer negotiations.
- Price projections indicate a downward trend, with list prices reducing by approximately 21% from 2023 to 2028.
FAQs
Q1: What factors most influence Rituximab's market price?
A: Biosimilar competition, payer negotiations, regulatory approvals, and treatment protocols.
Q2: How will biosimilar approval impact future prices?
A: Biosimilar adoption will drive prices down, with estimates of 10–20% reductions upon market entry.
Q3: What are primary indications driving revenue?
A: Non-Hodgkin lymphoma and chronic lymphocytic leukemia account for the majority of sales.
Q4: Are there upcoming regulatory changes affecting Rituximab?
A: Pending approval of new biosimilars and potential patents, which could alter market dynamics.
Q5: How does geographic variation affect pricing?
A: US prices are highest; Europe sees moderate reductions due to biosamilar competition, with lower prices in emerging markets.
Sources:
- IQVIA. (2023). Global Oncology Market Report.
- FDA. (2022). Approved Biosimilars for Oncology.
- IMS Health. (2023). Biologics Pricing Trends.
- Genentech. (2023). Rituximab Prescribing Information.
- European Medicines Agency. (2022). Biosimilar Guidance.
